Developer docs
API playgroundTry for free, no card

Search company profiles

Virica Biotech

Full company profile

uuid0002hcs

Namestring
Virica Biotech
Legal namestring
Virica Biotech Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Virica Biotech is an Ottawa-based biotechnology company founded in 2018 that develops proprietary Viral Sensitizer (VSE™) small molecule cell enhancers designed to temporarily suppress innate host cell antiviral defenses during viral vector production. By modulating these cellular responses, VSEs enable viruses to infect, transduce, and replicate more efficiently, addressing a fundamental bottleneck in viral vector manufacturing for cell and gene therapies. The company serves biotech and biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and vaccine producers across AAV, lentiviral, and vaccine production workflows, with reported yield improvements of 2-5x in standard AAV processes and up to 7x in broader applications, alongside projected 46-63% reductions in cost of goods per dose.

The company's product portfolio is built around four integrated assets: (1) the VSE™ small-molecule library, derived from screening more than 15,000 molecules; (2) CellVantage™ AAV, the first off-the-shelf catalog product launched in December 2025; (3) the High Throughput Virology (HTV™) screening platform that has evaluated VSE combinations across over 50 applications and cell-line/virus combinations; and (4) Viric.AI™, an active learning platform co-developed with the University of Ottawa that combines machine learning with iterative experimental feedback to optimize biomanufacturing conditions. The company operates a hybrid go-to-market model combining direct enterprise sales — led by a CCO (Beth Thompson-Webb, ex-Aldevron/Cytiva) and Head of Global Sales (Azra Benson, ex-Thermo Fisher/Danaher/Catalent) — for custom VSE formulations and collaborative development, alongside a self-service e-commerce storefront for standardized products. Revenue is generated through product sales (including the CellVantage™ AAV line), fee-for-service HTV screening, custom formulation development, and a meaningful layer of non-dilutive research funding from NRC IRAP, BioCanRx, FedDev Ontario, NIIMBL, and the Ontario Together Fund, with combined disclosed funding exceeding $5M since founding.

Short descriptiontext

Virica Biotech is an Ottawa-based biotechnology company developing Viral Sensitizer (VSE™) small molecules that boost viral vector yields by suppressing host cell defenses. It serves cell and gene therapy manufacturers, CDMOs, and vaccine producers through direct enterprise sales and e-commerce.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOttawa, Canada
HQ citystring
Ottawa
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
viral vector manufacturing, cell and gene therapy, bioprocessing optimization, small molecule enhancers, biopharmaceutical production
Industry4 codes
PRIMARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAJAL
Viral Clearance, Sterile Filtration & Bioburden Control Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Manufacturing Reagents
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1VSE Product Sales
TypeOne Time License
Description

Virica sells its proprietary Viral Sensitizer (VSE™) compounds as products to biotech companies, CDMOs, and gene therapy manufacturers. Products include CellVantage™ AAV and VSE starter kits. Revenue is generated through product sales with direct purchasing available via e-commerce.

viricabiotech.com
2Custom VSE Formulation Development
TypeProfessional Services
Description

The company develops customized VSE formulations for specific client applications and manufacturing processes. This includes application-specific VSE combinations optimized for particular cell lines and viral vectors.

viricabiotech.com
3Research Grants and Collaborations
TypeLicensing Royalties
Description

Virica receives funding through collaborative research projects with government agencies and industry partners, including BioCanRx grants, NIIMBL project funding, and NRC IRAP support.

viricabiotech.com
4High-Throughput Virology Services
TypeProfessional Services
Description

Fee-for-service screening and optimization services using the HTV platform to identify optimal VSE combinations for client-specific applications.

viricabiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1CellVantage AAV Product
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$345 per unit for CellVantage AAV; $995 for CellVantage AAV Starter Kit. Prices displayed for direct online purchase.

viricabiotech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Viral Sensitizers (VSE™)
Description

Proprietary small molecule cell enhancers that temporarily reduce host cell defenses during production, allowing viruses to infect, transduce, and replicate better, resulting in higher yields, quality, and scale-up success.

viricabiotech.com
+3 more records
Core offering1 text field

Virica Biotech develops and sells proprietary small molecule cell enhancers called Viral Sensitizers (VSE™) that temporarily reduce host cell antiviral defenses during viral vector and vaccine manufacturing, enabling higher yields, improved quality, and lower production costs. The company sells off-the-shelf VSE products (such as CellVantage™ AAV), provides custom formulation development, and operates the High Throughput Virology (HTV™) screening platform along with the Viric.AI™ active learning platform to optimize biomanufacturing processes for cell and gene therapy and vaccine producers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Up to 7x yield increase in viral vector production
+6 more records
Product overview1 text field

Virica Biotech is a cell enhancer company offering a platform technology centered on Viral Sensitizers (VSE™) - proprietary small molecule cell enhancers that temporarily reduce host cell defenses during production to boost viral vector and vaccine manufacturing yields. The core VSE™ Technology Platform serves as the foundation, from which specific application products like CellVantage™ AAV (an off-the-shelf additive for AAV production workflows) and CellVantage™ AAV Starter Kit are derived. The company also offers Viric.AI™, an active learning platform using machine learning for biomanufacturing optimization, and the HTV™ (High Throughput Virology) platform for screening and formulation development. VSEs are applicable across cell and gene therapies, lentiviral vector production, and vaccine manufacturing.

Product and service7 records
1VSE™ (Viral Sensitizers) Technology Platform
CategoryBiopharmaceutical Reagents
Description

Proprietary library of small molecule cell enhancers called Viral Sensitizers that temporarily reduce host cell antiviral defenses during production, allowing viruses to infect, transduce, and replicate better. Results in higher yields (up to 7x), improved quality attributes, and better scale-up success for viral vector and vaccine manufacturing. Sold to biotech companies, CDMOs, and gene therapy manufacturers.

2CellVantage™ AAV
CategoryBiopharmaceutical Reagents
Description

Off-the-shelf VSE enhancer product designed to drop into existing AAV (adeno-associated virus) production workflows to increase upstream yield. Developed from screening over 15,000 molecules, delivering 2-5x increase in genomic and functional AAV titers across multiple suspension HEK293-based platforms. Targeted at gene therapy manufacturers.

3CellVantage™ AAV Starter Kit
CategoryBiopharmaceutical Reagents
Description

Smaller package offering for customers to evaluate CellVantage™ AAV before full-scale adoption. Allows prospective buyers to test the product's performance in their own workflows prior to committing to larger volumes.

4Viric.AI™
CategoryBiomanufacturing Software
Description

Proprietary active learning platform that combines machine learning with iterative experimental feedback to guide experimental design, identify high-value conditions earlier, reduce development timelines, and improve yield optimization in biomanufacturing. Targeted at biomanufacturers developing gene therapies and vaccines.

5HTV™ (High Throughput Virology) Platform
CategoryBiomanufacturing Services
Description

Proprietary high-throughput screening platform ensuring purpose-built and optimal VSE combinations for current and emergent viral vector and vaccine manufacturing applications. Evaluated across 50+ cell line and virus combinations. Used for fee-for-service screening and optimization engagements with clients.

6Custom VSE Formulation Development
CategoryBiomanufacturing Services
Description

Professional service in which Virica develops customized VSE formulations optimized for specific client applications, cell lines, and viral vector manufacturing processes. Targeted at biotech and gene therapy manufacturers requiring tailored optimization.

7High-Throughput Virology Screening Services
CategoryBiomanufacturing Services
Description

Fee-for-service screening and optimization services using the HTV platform to identify optimal VSE combinations for client-specific applications in viral vector production. Targeted at CDMOs, biotech companies, and academic manufacturing centers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals) public-private partnership funding 39 awards to support domestic biopharmaceutical production. Virica participates in MIT-led consortium with EMD Millipore and Landmark Bio to reduce empty viral capsids in AAV production.

Strategic tierImportantTypeTechnology or IntegrationAnnounced on2026-04-23
Description

Collaboration developing Viric.AI active learning platform. Combines machine learning with iterative experimental feedback for biomanufacturing optimization. Platform being deployed through Canada's Pandemic Preparedness Hub (CP2H).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

Collaboration under the NRC IRAP Canada-Japan Corporate Co-Innovation Program to optimize Virica's VSE formulation for FUJIFILM Biosciences' BalanCD HEK293 media. Project aims to create an off-the-shelf enhancer-media combination for gene therapy manufacturers, combining Virica's HTV platform with FUJIFILM's media expertise and scale-up capabilities to improve AAV productivity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-06
Description

$1 million collaborative project with Dr. Jean-Simon Diallo's lab selected for BioCanRx grant financing. Project generates regulatory assays and procedures to advance VSE technology for lentiviral production used by academic institutes and large-scale producers including BMC.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-18
Description

Collaboration funded by Canada-UK government initiative to develop VSE formulations for AAV production at scale. Project leverages Virica's VSE technology and eXmoor's process development expertise to reduce gene therapy manufacturing costs. Expected to complete in 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-10
Description

Strategic partnership to improve AAV gene therapy manufacturing. Virica provides its VSE panel for high-throughput AAV production screening while Ginkgo utilizes its advanced screening platform to test VSEs directly in clients' cell lines. Aims to reduce high AAV manufacturing costs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-11
Description

Virica leads NIIMBL project to enhance CAR-T manufacturing using small-molecule enhancers. Project aims to increase lentiviral vector production outputs, cut costs, and improve manufacturing efficiency. Supported by NIIMBL members AstraZeneca and Sartorius Stedim Biotech.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

Multi-year, multi-million-dollar research and infrastructure partnership. Virica's new facility at Carleton University expands bioprocessing services and enables talent development with experiential learning opportunities for students. Partnership drives innovation in advanced therapy manufacturing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing collaboration providing advisory services and funding through NRC IRAP. Supports Canada-Japan Co-Innovation Program projects and other international collaboration initiatives.

Strategic tierImportantTypeStrategic or Co-development Partner
Description

Collaboration on AAV production optimization in ELEVECTA transient cell line. Joint development of VSE formulations validated at 10L scale demonstrating 2-4 fold titer improvements and 63% cost reduction potential.

11Culture Biosciences
Strategic tierImportantTypeStrategic or Co-development Partner
Description

Collaboration using cloud-connected 250mL bioreactors with Virica's VSE enhancers and DoE optimization. Achieved 2-5 fold AAV titer improvements. Enables rapid screening and scalable process optimization.

viricabiotech.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ReiThera is a biotech developing vaccines and gene therapies using its proprietary ReiCell-AAV cell line. Its partnership with Virica integrated VSEs into ReiThera's AAV platform, achieving 3-4 fold productivity improvements in a directly comparable application.

TypeDirect peer
Description

FUJIFILM Biosciences provides cell culture media (including BalanCD HEK293) and process development services for biomanufacturing. Its Canada-Japan co-innovation partnership with Virica is creating an off-the-shelf enhancer-media combination for gene therapy manufacturers.

TypeDirect peer
Description

Aldevron (acquired by Danaher) manufactured plasmid DNA, mRNA, and proteins for gene therapy and vaccine developers. It serves an overlapping customer base to Virica; Virica's current CCO previously led commercial at Aldevron.

TypeDirect peer
Description

Ginkgo Bioworks provides cell programming and biomanufacturing services, including high-throughput AAV production screening. Its strategic partnership with Virica integrates VSEs into Ginkgo's screening services for gene therapy clients.

TypeDirect peer
Description

Cytiva (a Danaher company) provides media, bioreactors, and process development services for cell and gene therapy manufacturing. It is both a Virica partner (ELEVECTA cell line co-development) and a competing supplier of upstream bioprocess solutions.

TypeBroad incumbent
Description

Lonza is a global CDMO with significant cell and gene therapy manufacturing capacity, offering media, process development, and viral vector production services that compete broadly with Virica's served market.

TypeBroad incumbent
Description

Thermo Fisher's life sciences tools and bioproduction businesses serve cell and gene therapy manufacturers with media, reagents, and process services. As a large incumbent it competes indirectly in upstream yield optimization and has historically employed Virica's commercial leadership.

8Culture Biosciences
TypeDirect peer
Description

Culture Biosciences operates cloud-connected bioreactors for bioprocess development and optimization. It partners with Virica to combine its 250mL bioreactor platform with VSE enhancers and DoE optimization for AAV clients.

TypeDirect peer
Description

eXmoor Pharma is a CDMO specializing in cell and gene therapy process development and manufacturing. Its UK-Canada partnership with Virica combines VSE formulations with eXmoor's AAV process development expertise to deliver scaled yield improvements.

TypeBroad incumbent
Description

Sartorius offers bioprocessing equipment, consumables, and reagents for viral vector and vaccine manufacturing. It is also a NIIMBL project partner supporting Virica's CAR-T work, but its broader bioprocess portfolio creates competitive overlap in upstream yield optimization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Virica Biotech

Biopharmaceutical Manufacturing Reagentsviricabiotech.com

Virica Biotech is an Ottawa-based biotechnology company developing Viral Sensitizer (VSE™) small molecules that boost viral vector yields by suppressing host cell defenses. It serves cell and gene therapy manufacturers, CDMOs, and vaccine producers through direct enterprise sales and e-commerce.

What Virica Biotech does

Virica Biotech is an Ottawa-based biotechnology company founded in 2018 that develops proprietary Viral Sensitizer (VSE™) small molecule cell enhancers designed to temporarily suppress innate host cell antiviral defenses during viral vector production. By modulating these cellular responses, VSEs enable viruses to infect, transduce, and replicate more efficiently, addressing a fundamental bottleneck in viral vector manufacturing for cell and gene therapies. The company serves biotech and biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and vaccine producers across AAV, lentiviral, and vaccine production workflows, with reported yield improvements of 2-5x in standard AAV processes and up to 7x in broader applications, alongside projected 46-63% reductions in cost of goods per dose.

The company's product portfolio is built around four integrated assets: (1) the VSE™ small-molecule library, derived from screening more than 15,000 molecules; (2) CellVantage™ AAV, the first off-the-shelf catalog product launched in December 2025; (3) the High Throughput Virology (HTV™) screening platform that has evaluated VSE combinations across over 50 applications and cell-line/virus combinations; and (4) Viric.AI™, an active learning platform co-developed with the University of Ottawa that combines machine learning with iterative experimental feedback to optimize biomanufacturing conditions. The company operates a hybrid go-to-market model combining direct enterprise sales — led by a CCO (Beth Thompson-Webb, ex-Aldevron/Cytiva) and Head of Global Sales (Azra Benson, ex-Thermo Fisher/Danaher/Catalent) — for custom VSE formulations and collaborative development, alongside a self-service e-commerce storefront for standardized products. Revenue is generated through product sales (including the CellVantage™ AAV line), fee-for-service HTV screening, custom formulation development, and a meaningful layer of non-dilutive research funding from NRC IRAP, BioCanRx, FedDev Ontario, NIIMBL, and the Ontario Together Fund, with combined disclosed funding exceeding $5M since founding.

Virica Biotech firmographics

Firmographics
Name
Virica Biotech
Legal name
Virica Biotech Inc.
Website
https://viricabiotech.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Virica Biotech is an Ottawa-based biotechnology company developing Viral Sensitizer (VSE™) small molecules that boost viral vector yields by suppressing host cell defenses. It serves cell and gene therapy manufacturers, CDMOs, and vaccine producers through direct enterprise sales and e-commerce.
Ownership category
akta.pro rank

Virica Biotech industry classification

Industry
Product category
Biopharmaceutical Manufacturing Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAJAL
Viral Clearance, Sterile Filtration & Bioburden Control Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Viral vector manufacturing
  • Cell and gene therapy
  • Bioprocessing optimization
  • Small molecule enhancers
  • Biopharmaceutical production

Where Virica Biotech is headquartered

Location

Headquarters

HQ city
Ottawa
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Virica Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. VSE Product Sales: Virica sells its proprietary Viral Sensitizer (VSE™) compounds as products to biotech companies, CDMOs, and gene therapy manufacturers. Products include CellVantage™ AAV and VSE starter kits. Revenue is generated through product sales with direct purchasing available via e-commerce.
  2. Custom VSE Formulation Development: The company develops customized VSE formulations for specific client applications and manufacturing processes. This includes application-specific VSE combinations optimized for particular cell lines and viral vectors.
  3. Research Grants and Collaborations: Virica receives funding through collaborative research projects with government agencies and industry partners, including BioCanRx grants, NIIMBL project funding, and NRC IRAP support.
  4. High-Throughput Virology Services: Fee-for-service screening and optimization services using the HTV platform to identify optimal VSE combinations for client-specific applications.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCellVantage AAV Product

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Virica Biotech product offering

Product offering

Core offering

Virica Biotech develops and sells proprietary small molecule cell enhancers called Viral Sensitizers (VSE™) that temporarily reduce host cell antiviral defenses during viral vector and vaccine manufacturing, enabling higher yields, improved quality, and lower production costs. The company sells off-the-shelf VSE products (such as CellVantage™ AAV), provides custom formulation development, and operates the High Throughput Virology (HTV™) screening platform along with the Viric.AI™ active learning platform to optimize biomanufacturing processes for cell and gene therapy and vaccine producers.

Product overview

Virica Biotech is a cell enhancer company offering a platform technology centered on Viral Sensitizers (VSE™) - proprietary small molecule cell enhancers that temporarily reduce host cell defenses during production to boost viral vector and vaccine manufacturing yields. The core VSE™ Technology Platform serves as the foundation, from which specific application products like CellVantage™ AAV (an off-the-shelf additive for AAV production workflows) and CellVantage™ AAV Starter Kit are derived. The company also offers Viric.AI™, an active learning platform using machine learning for biomanufacturing optimization, and the HTV™ (High Throughput Virology) platform for screening and formulation development. VSEs are applicable across cell and gene therapies, lentiviral vector production, and vaccine manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • Viral Sensitizers (VSE™): Proprietary small molecule cell enhancers that temporarily reduce host cell defenses during production, allowing viruses to infect, transduce, and replicate better, resulting in higher yields, quality, and scale-up success.
  • CellVantage™ AAV
  • Viric.AI™
  • HTV™ (High Throughput Virology)

Products and services

  • VSE™ (Viral Sensitizers) Technology Platform Proprietary library of small molecule cell enhancers called Viral Sensitizers that temporarily reduce host cell antiviral defenses during production, allowing viruses to infect, transduce, and replicate better. Results in higher yields (up to 7x), improved quality attributes, and better scale-up success for viral vector and vaccine manufacturing. Sold to biotech companies, CDMOs, and gene therapy manufacturers.
  • CellVantage™ AAV Off-the-shelf VSE enhancer product designed to drop into existing AAV (adeno-associated virus) production workflows to increase upstream yield. Developed from screening over 15,000 molecules, delivering 2-5x increase in genomic and functional AAV titers across multiple suspension HEK293-based platforms. Targeted at gene therapy manufacturers.
  • CellVantage™ AAV Starter Kit Smaller package offering for customers to evaluate CellVantage™ AAV before full-scale adoption. Allows prospective buyers to test the product's performance in their own workflows prior to committing to larger volumes.
  • Viric.AI™ Proprietary active learning platform that combines machine learning with iterative experimental feedback to guide experimental design, identify high-value conditions earlier, reduce development timelines, and improve yield optimization in biomanufacturing. Targeted at biomanufacturers developing gene therapies and vaccines.
  • HTV™ (High Throughput Virology) Platform Proprietary high-throughput screening platform ensuring purpose-built and optimal VSE combinations for current and emergent viral vector and vaccine manufacturing applications. Evaluated across 50+ cell line and virus combinations. Used for fee-for-service screening and optimization engagements with clients.
  • Custom VSE Formulation Development Professional service in which Virica develops customized VSE formulations optimized for specific client applications, cell lines, and viral vector manufacturing processes. Targeted at biotech and gene therapy manufacturers requiring tailored optimization.
  • High-Throughput Virology Screening Services Fee-for-service screening and optimization services using the HTV platform to identify optimal VSE combinations for client-specific applications in viral vector production. Targeted at CDMOs, biotech companies, and academic manufacturing centers.

Quantifiable outcome

  • Up to 7x yield increase in viral vector production
  • +6 more outcomes

Companies that use Virica Biotech

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Virica Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Virica Biotech partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and important.

  • NIIMBLcoreStrategic or Co-development Partner · 3 June 2026NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals) public-private partnership funding 39 awards to support domestic biopharmaceutical production. Virica participates in MIT-led consortium with EMD Millipore and Landmark Bio to reduce empty viral capsids in AAV production.
  • University of Ottawa (Dr. Francesco Gentile's lab)importantTechnology or Integration · 23 April 2026Collaboration developing Viric.AI active learning platform. Combines machine learning with iterative experimental feedback for biomanufacturing optimization. Platform being deployed through Canada's Pandemic Preparedness Hub (CP2H).
  • FUJIFILM BiosciencescoreStrategic or Co-development Partner · 8 April 2026Collaboration under the NRC IRAP Canada-Japan Corporate Co-Innovation Program to optimize Virica's VSE formulation for FUJIFILM Biosciences' BalanCD HEK293 media. Project aims to create an off-the-shelf enhancer-media combination for gene therapy manufacturers, combining Virica's HTV platform with FUJIFILM's media expertise and scale-up capabilities to improve AAV productivity.
  • Ottawa Hospital Research InstitutecoreStrategic or Co-development Partner · 6 March 2025$1 million collaborative project with Dr. Jean-Simon Diallo's lab selected for BioCanRx grant financing. Project generates regulatory assays and procedures to advance VSE technology for lentiviral production used by academic institutes and large-scale producers including BMC.
  • eXmoor pharmacoreStrategic or Co-development Partner · 18 October 2024Collaboration funded by Canada-UK government initiative to develop VSE formulations for AAV production at scale. Project leverages Virica's VSE technology and eXmoor's process development expertise to reduce gene therapy manufacturing costs. Expected to complete in 2025.
  • Ginkgo BioworkscoreStrategic or Co-development Partner · 10 October 2024Strategic partnership to improve AAV gene therapy manufacturing. Virica provides its VSE panel for high-throughput AAV production screening while Ginkgo utilizes its advanced screening platform to test VSEs directly in clients' cell lines. Aims to reduce high AAV manufacturing costs.
  • NIIMBL (with AstraZeneca and Sartorius Stedim Biotech)coreStrategic or Co-development Partner · 11 April 2024Virica leads NIIMBL project to enhance CAR-T manufacturing using small-molecule enhancers. Project aims to increase lentiviral vector production outputs, cut costs, and improve manufacturing efficiency. Supported by NIIMBL members AstraZeneca and Sartorius Stedim Biotech.
  • Carleton UniversitycoreStrategic or Co-development Partner · 17 January 2024Multi-year, multi-million-dollar research and infrastructure partnership. Virica's new facility at Carleton University expands bioprocessing services and enables talent development with experiential learning opportunities for students. Partnership drives innovation in advanced therapy manufacturing.
  • National Research Council of Canada (NRC)coreStrategic or Co-development PartnerOngoing collaboration providing advisory services and funding through NRC IRAP. Supports Canada-Japan Co-Innovation Program projects and other international collaboration initiatives.
  • CytivaimportantStrategic or Co-development PartnerCollaboration on AAV production optimization in ELEVECTA transient cell line. Joint development of VSE formulations validated at 10L scale demonstrating 2-4 fold titer improvements and 63% cost reduction potential.
  • Culture BiosciencesimportantStrategic or Co-development PartnerCollaboration using cloud-connected 250mL bioreactors with Virica's VSE enhancers and DoE optimization. Achieved 2-5 fold AAV titer improvements. Enables rapid screening and scalable process optimization.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Virica Biotech competitors and assessment

Company assessment

Direct peers

  • ReiThera: ReiThera is a biotech developing vaccines and gene therapies using its proprietary ReiCell-AAV cell line. Its partnership with Virica integrated VSEs into ReiThera's AAV platform, achieving 3-4 fold productivity improvements in a directly comparable application.
  • FUJIFILM Biosciences: FUJIFILM Biosciences provides cell culture media (including BalanCD HEK293) and process development services for biomanufacturing. Its Canada-Japan co-innovation partnership with Virica is creating an off-the-shelf enhancer-media combination for gene therapy manufacturers.
  • Aldevron: Aldevron (acquired by Danaher) manufactured plasmid DNA, mRNA, and proteins for gene therapy and vaccine developers. It serves an overlapping customer base to Virica; Virica's current CCO previously led commercial at Aldevron.
  • Ginkgo Bioworks: Ginkgo Bioworks provides cell programming and biomanufacturing services, including high-throughput AAV production screening. Its strategic partnership with Virica integrates VSEs into Ginkgo's screening services for gene therapy clients.
  • Cytiva: Cytiva (a Danaher company) provides media, bioreactors, and process development services for cell and gene therapy manufacturing. It is both a Virica partner (ELEVECTA cell line co-development) and a competing supplier of upstream bioprocess solutions.
  • Culture Biosciences: Culture Biosciences operates cloud-connected bioreactors for bioprocess development and optimization. It partners with Virica to combine its 250mL bioreactor platform with VSE enhancers and DoE optimization for AAV clients.
  • eXmoor Pharma: eXmoor Pharma is a CDMO specializing in cell and gene therapy process development and manufacturing. Its UK-Canada partnership with Virica combines VSE formulations with eXmoor's AAV process development expertise to deliver scaled yield improvements.

Broad incumbents

  • Lonza: Lonza is a global CDMO with significant cell and gene therapy manufacturing capacity, offering media, process development, and viral vector production services that compete broadly with Virica's served market.
  • Thermo Fisher Scientific: Thermo Fisher's life sciences tools and bioproduction businesses serve cell and gene therapy manufacturers with media, reagents, and process services. As a large incumbent it competes indirectly in upstream yield optimization and has historically employed Virica's commercial leadership.
  • Sartorius Stedim Biotech: Sartorius offers bioprocessing equipment, consumables, and reagents for viral vector and vaccine manufacturing. It is also a NIIMBL project partner supporting Virica's CAR-T work, but its broader bioprocess portfolio creates competitive overlap in upstream yield optimization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Virica Biotech social profiles

Digital presence

Virica Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Virica Biotech leadership team

Management profile

Number of profiles

Profiles10 records

Virica Biotech funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Virica Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virica Biotech

What does Virica Biotech do?

Virica Biotech develops and sells proprietary small molecule cell enhancers called Viral Sensitizers (VSE™) that temporarily reduce host cell antiviral defenses during viral vector and vaccine manufacturing, enabling higher yields, improved quality, and lower production costs. The company sells off-the-shelf VSE products (such as CellVantage™ AAV), provides custom formulation development, and operates the High Throughput Virology (HTV™) screening platform along with the Viric.AI™ active learning platform to optimize biomanufacturing processes for cell and gene therapy and vaccine producers.

Is Virica Biotech a public or private company?

Virica Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Virica Biotech founded?

Virica Biotech was founded in 2018. It employs 11 to 50 people.

Where is Virica Biotech based?

Virica Biotech is headquartered in Ottawa, Canada, in the North America region.

How does Virica Biotech make money?

Four revenue lines are on record. VSE Product Sales are the primary driver. The others are custom VSE Formulation Development, research Grants and Collaborations and high-Throughput Virology Services.

Who are Virica Biotech's main competitors?

Direct peers on record are ReiThera, FUJIFILM Biosciences, Aldevron, Ginkgo Bioworks, Cytiva, Culture Biosciences and eXmoor Pharma. Broad incumbents are Lonza, Thermo Fisher Scientific and Sartorius Stedim Biotech.

Does Virica Biotech have an API?

No public API is recorded for Virica Biotech.

What industry is Virica Biotech in?

Virica Biotech's product category is Biopharmaceutical Manufacturing Reagents. Its primary akta.pro industry code is HLAAAKAD, Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsNIIMBL to Support Vector Production and AI-Ready Training ProjectsNIIMBL, a U.S. public-private partnership focused on biopharmaceutical manufacturing innovation, announced 39 funding awards to support domestic production and talent development. Several projects focus on improving adeno-associated viral vector production for gene therapy, including work by Michigan Technological University, North Carolina State, and an MIT-led consortium with EMD Millipore, Landmark Bio, and Virica Biotech to reduce empty viral capsids. Additional initiatives include workforce training programs such as Texas A&M University's NeuroPipes program for neurodiverse adults and the Wistar Institute's BioPATH national consortium focused on biomanufacturing, AI, and automation.Via TTVirica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production EnhancersVirica Biotech announced a collaboration with FUJIFILM Biosciences under the Canada–Japan Corporate Co-Innovation Program, supported by NRC IRAP advisory services and funding, to optimize Virica's Viral Sensitizer (VSE™) formulation for FUJIFILM Biosciences' BalanCD HEK293 media. The partnership aims to significantly improve AAV productivity and create an off-the-shelf enhancer-media combination for gene therapy manufacturers, addressing the high cost and scalability challenges of AAV production at scale. This collaboration combines Virica's High-Throughput Virology platform with FUJIFILM Biosciences' media expertise and scale-up capabilities.BioProcess InternationalSmall-Molecule Yield Enhancers in AAV ProductionVirica Biotech, in collaboration with Inspire Biotherapeutics and the Ottawa Hospital Research Institute's Biotherapeutics Manufacturing Centre, used a high-throughput design-of-experiments platform combined with proprietary small-molecule Viral Sensitizers (VSEs) to optimize upstream AAV6 vector production for rare-disease gene therapies. The approach achieved 3–6× gains in viral-genome titer over baseline conditions without increasing plasmid DNA input, with the top formulation reaching average titers of 1.5 × 10¹¹ vg/mL. Researchers project these yield improvements could reduce cost of goods per dose by 46–63%, addressing a central manufacturing bottleneck that limits scalability, cost-efficiency, and patient access for AAV-based gene therapies.NewsfileVirica Biotech Introduces Viric.AI, an Active Learning Platform to Accelerate Biomanufacturing OptimizationVirica Biotech launched Viric.AI, an active learning platform for optimizing biomanufacturing enhancers, developed with the University of Ottawa. It is being used by the Canadian Pandemic Preparedness Hub to discover enhancers for adenovirus production, supporting both commercial and public health efforts.BioSpaceVirica Biotech Introduces Viric.AI, an Active Learning Platform to Accelerate Biomanufacturing OptimizationVirica Biotech launched Viric.AI, an active learning platform that combines machine learning with iterative experimental feedback to accelerate biomanufacturing enhancer discovery. The platform is being used by the Canadian Pandemic Preparedness Hub to find novel enhancers for adenovirus production, highlighting dual-use potential for commercial and public health applications.ContractpharmaVirica Biotech, FUJIFILM Biosciences Partner to Advance AAV Production EnhancersVirica Biotech has partnered with FUJIFILM Biosciences to optimize a Viral Sensitizer formulation for AAV production using FUJIFILM's BalanCD HEK293 media, with the goal of improving scalability and reducing manufacturing costs. The collaboration aims to address the longstanding challenge of producing AAV vectors—which are critical for gene therapies—at scale and at commercially viable costs. The project is supported by Canada's National Research Council Industrial Research Assistance Program under the Canada–Japan Corporate Co-Innovation Program.Business Wire BlogVirica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production EnhancersVirica Biotech has entered into a collaboration with FUJIFILM Biosciences under the Canada–Japan Corporate Co-Innovation Program, supported by NRC IRAP, to optimize viral vector production enhancers for gene therapy applications. The partnership aims to improve AAV (adeno-associated virus) productivity by combining Virica's VSE™ technology with FUJIFILM Biosciences' BalanCD HEK293 media system, addressing the manufacturing challenges and cost constraints facing the gene therapy industry. The collaboration seeks to deliver an off-the-shelf enhancer-media combination that can be adopted with minimal process changes by academic and commercial AAV producers globally.BioSpaceVirica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production EnhancersVirica Biotech and FUJIFILM Biosciences have entered a collaboration under the Canada–Japan Corporate Co-Innovation Program, supported by NRC IRAP, to co-develop an off-the-shelf enhancer-media solution that optimizes AAV yields in the FUJIFILM Biosciences BalanCD HEK293 system. The partnership aims to address the manufacturing bottleneck in AAV vector production for in vivo gene therapies by combining Virica's Viral Sensitizer (VSE™) technology with FUJIFILM Biosciences' media expertise. This collaboration seeks to deliver significant productivity gains and more scalable, commercially viable manufacturing processes for gene therapy developers globally.Challenge What's PossibleFast-Tracking Drug TherapiesCarleton University biochemists Kyle Biggar and Jeff Smith are collaborating with startup companies NuvoBio and Virica, supported by Capital BioVentures, to accelerate pharmaceutical research and bring treatments to market more quickly and affordably. NuvoBio, co-founded by Biggar and former Corel CEO Michael Cowpland, is developing NeoPeptix, a peptide therapeutic for fungal meningitis caused by Cryptococcus neoformans, with plans to seek FDA clinical trial authorization by 2027; early preclinical tests show significantly higher potency than existing treatments. Virica, located beside NuvoBio on Carleton's campus, produces proprietary cell enhancers that improve viral medicine manufacturing yield and quality, potentially reducing financial barriers to gene therapies for diseases including cancer, cystic fibrosis, and diabetes.PharmiWeb.comeXmoor and Virica receive funding to improve AAV gene therapy manufacturingeXmoor pharma and Virica Biotech Inc. have announced a collaborative project funded by the Canada-UK government program BRISTOL to improve adeno-associated vector (AAV) manufacturing. The partnership will leverage Virica’s VSEs™ small molecules and eXmoor’s scale-up expertise to develop formulations that increase AAV yields and lower commercial production costs. The project is supported by funding from Innovate UK and the National Research Council of Canada Industrial Research Assistance Program.